Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly …
Summit says FDA will decide to approve its cancer drug by November
The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted

